Pricing Log in Create free account
Saturday 17 October 2026 Export LFMD’s income statement to Excel — free account

LifeMD, Inc.

LFMD Healthcare Health Information Services

LifeMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $194.1 million, up 25.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.55%, EPS fell 166.7% and free cash flow fell 247.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

2.34 0.12 −4.88%
Market cap
$118.6M
P/E
0.0×
Fwd P/E
−17.9×
Dividend yield
—
F-score
6/9
Altman Z
−0.02
Beneish M
−3.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 1 — — — — — — — — — —
Insider Ownership 18.03%

Capital & Financial Ratios $m

Market Cap 118.58
Revenue 191.59
Net Income 0.43
Free Cash Flow (18.28)
Net Debt (25.14)
Current Ratio 0.90 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (17.90) (negative: loss-making)
P/S ratio 0.58
P/B ratio 14.04 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (307.43%) (below 0%: weak)
Next Y EPS Growth 82.37% (at or above 15%: strong)
Next Y revenue growth 6.98%
Next 5Y EPS Growth (15.28%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.5×, against a ten-year median of 1.5×; over the ten years it ranged from 0.4× in 2022 to 8.2× in 2021.
P/S against its own 10 years 9.03%
10-year low 10-year high
P/B against its own 10 years 33.83%
10-year low 10-year high
EV/Sales against its own 10 years 9.69%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 33 33 37 25
Receivables 5 10 9 11
Inventory 3 3 3 3
Other 1 3 3 3
43 52 52 42
2023 2024 2025 Q'26
Payables 11 11 14 18
ST’ Debt — 8 — —
Other — — — —
35 67 42 47

Compound Annual Growth %

10y 5y 3y
Sales 66.03% 39.08% 17.69%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 62.44% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 50 47 — — —
’25 51 49 60 34 194
’24 44 51 53 7 155
’23 33 36 39 45 153
’22 29 30 31 28 119
’21 18 22 25 27 93
’20 4 9 11 13 37
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 (7) — — —
’25 3 9 0 (3) 8
’24 5 5 7 1 18
’23 (3) 5 1 6 9
’22 (8) (10) (3) (2) (23)
’21 (9) (11) (7) (6) (33)
’20 1 (2) (4) (7) (12)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (9) — — —
’25 1 6 (5) (3) (1)
’24 3 1 3 2 9
’23 (4) 2 (1) 3 0
’22 (14) (13) (5) (4) (36)
’21 (9) (12) (8) (7) (36)
’20 1 (2) (5) (7) (13)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.20) (0.16) — — —
’25 0.01 (0.06) (0.10) 0.41 0.25
’24 (0.19) (0.19) (0.14) (0.02) (0.53)
’23 (0.15) (0.23) (0.20) (0.12) (0.70)
’22 (0.46) (0.45) (0.26) (0.40) (1.57)
’21 (0.47) (0.64) (0.54) (0.62) (2.29)
’20 (0.25) (0.30) (1.65) (2.56) (4.44)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 0.50 1.05 0.60 0.40 0.50 3.70 1.72 1.14 3.99 3.18

Analyst estimates 2026–2028

Powerpack
High 2.00 4.75 1.95 1.00 10.70 33.02 4.33 9.11 12.88 15.84
People
People Employees 11 10 16 26 56 232 220 232 336 389
Revenue/emp, $m 0.48 0.37 0.52 0.48 0.67 0.40 0.54 0.66 0.46 0.50
Income, $m
Income, $m Revenue 5 4 8 12 37 93 119 153 155 194
Gross margin, % 62.85 72.36 76.02 79.75 76.24 80.62 84.32 87.61 86.15 85.72
EBT (1) (1) (2) (4) (60) (61) (45) (17) (23) (10)
EBT margin, % (23.35) (37.46) (28.96) (29.28) (161.96) (66.02) (37.52) (11.41) (14.58) (5.25)
Net income (1) (1) (1) (4) (61) (61) (45) (18) (21) 16
Depreciation 0 0 1 1 1 3 13 7 7 8
Per share, $
Per share, $ Revenue 0.78 0.44 0.94 1.26 2.61 3.44 3.84 4.50 3.76 4.30
Earnings (0.17) (0.15) (0.10) (0.35) (4.44) (2.29) (1.57) (0.70) (0.53) 0.25
Cash flow (0.06) (0.10) (0.10) 0.03 (0.85) (1.22) (0.74) 0.26 0.43 0.18
Capex 0.00 0.00 (0.01) 0.00 (0.03) (0.13) (0.42) (0.26) (0.20) (0.21)
Free cash flow (0.06) (0.10) (0.11) 0.03 (0.88) (1.35) (1.16) 0.00 0.23 (0.03)
Book value (0.05) 0.07 0.09 (0.11) (0.06) 0.96 (0.24) 0.16 (0.18) 0.51
Shares, m 7 8 9 10 14 27 31 34 41 45
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.12
P/S 1.53 4.08 0.74 0.48 2.50 1.13 0.49 1.87 1.32 0.79
P/B 0.00 24.13 7.55 0.00 0.00 4.81 0.00 51.35 0.00 6.65
EV/Sales 1.52 4.07 0.73 0.46 2.28 0.70 0.49 1.78 1.22 0.68
EV/FCF (19.50) (18.34) (6.70) 22.58 (6.76) (1.78) (1.64) 3,127.18 20.37 (106.73)
Cash, $m
Cash, $m Operating cash flow 0 (1) (1) 0 (12) (33) (23) 9 18 8
Capex — — 0 — 0 (3) (13) (9) (8) (10)
Free cash flow 0 (1) (1) 0 (13) (36) (36) 0 9 (1)
Balance, $m
Balance, $m Working capital 0 1 0 (1) (2) 22 (20) 8 (15) 10
Total debt 0 0 0 1 1 2 4 18 18 —
Net debt 0 0 0 0 (8) (39) 0 (15) (14) (37)
Shareholders’ equity 0 1 1 (1) (1) 26 (7) 6 (8) 23
Returns, %
Returns, % ROA (178.87) (117.45) (63.96) (103.50) (752.12) (195.08) (128.70) (56.34) (36.43) 15.35
ROIC 0.00 (118.32) (144.88) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE 1,225.79 (923.78) (172.03) 2,027.27 2,260.22 (716.97) (988.99) 751.79 2,465.96 144.18
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

LifeMD, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SPOK Spok Holdings, Inc. $224.5M 17.7× 16.2× −1.89% (below 0%: shrinking) −9.09% (below 0%: shrinking) −2.00% (below 0%: shrinking) 80.47% 15.50% Compare
AMWL American Well Corporation $210.6M — (loss-making) — (loss-making) −26.59% (below 0%: shrinking) n/m +266.38% (above 0%: growing) 52.95% (18.36%) Compare
SY So-Young International Inc. Sponsored ADR $198.9M — (loss-making) 12.8× +40.84% (above 0%: growing) n/m −798.37% (below 0%: shrinking) 44.11% (8.64%) Compare
OPRX OptimizeRx Corp. $166.7M 35.4× 23.0× −29.77% (below 0%: shrinking) n/m +89.86% (above 0%: growing) 76.51% (0.43%) Compare
DH Definitive Healthcare Corp. $144.3M — (loss-making) — (loss-making) −9.14% (below 0%: shrinking) n/m +21.44% (above 0%: growing) 73.45% (12.23%) Compare
HCAT Health Catalyst, Inc. $135.5M — (loss-making) — (loss-making) −12.68% (below 0%: shrinking) n/m +64.26% (above 0%: growing) 49.46% (51.75%) Compare
LFMD LifeMD, Inc. $118.6M — (loss-making) — (loss-making) −3.55% (below 0%: shrinking) n/m −247.52% (below 0%: shrinking) 88.82% (15.08%)
CCLD CareCloud, Inc. $82.0M 26.4× 12.5× +16.45% (above 0%: growing) n/m +6.15% (above 0%: growing) 45.24% 5.84% Compare
DRIO DarioHealth Corp. $50.3M — (loss-making) — (loss-making) −3.58% (below 0%: shrinking) n/m −0.74% (below 0%: shrinking) 61.66% (125.15%) Compare
Median of peers $155.5M 26.4× 14.5× −6.36% — +13.80% 57.31% (10.43%)

All 51 Health Information Services stocks →

LifeMD, Inc. (LFMD) key facts

  • Strength: LifeMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $194.1 million, up 25.3% from fiscal 2024.
  • LifeMD, Inc. (LFMD) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LFMD traded at $2.34, a market capitalization of $118.6 million.
  • Return on equity was 144.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −0.02 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

LifeMD, Inc. (LFMD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LFMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com